How Racism Is Shaping the Coronavirus Pandemic
By Isaac Chotiner,
The New Yorker
| 05. 07. 2020
The historian Evelynn Hammonds talks about how false theories of “innate difference and deficit in black bodies” have shaped American responses to disease, from yellow fever to syphilis to COVID-19.
Evelynn Hammonds, who chairs Harvard’s department of the history of science, has spent her career studying the intersection of race and disease. She wrote a history of New York City’s attempt, a century ago, to control diphtheria, and is currently at work on a book of essays on the history of race, from Jefferson to genomics. Hammonds’s area of expertise is especially relevant today: while the data is incomplete, at this point in time, African-Americans represent nearly a third of U.S. deaths from the coronavirus pandemic and thirty per cent of covid-19 cases, despite making up only about thirteen per cent of the population. Hammonds noted recently, “This new development of what has happened with the pandemic with respect to African-American communities” is “perhaps an old development.”
I spoke by phone with Hammonds, who is currently hosting a series of Webinars with academics and experts at Harvard on African-Americans and epidemics in American history, from the eighteenth century to the present day. As she stated in one of the sessions, “I can’t imagine saying that we have to...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...